Nine young women, suffering from debilitating diseases that occurred after their vaccination, filed a complaint against X.
Nine additional complaints were lodged with the court of Bobigny, in Seine-Saint-Denis, by young women who were vaccinated with Gardasil, the vaccine indicated in the prevention of precancerous and cancerous lesions of the cervix due to certain infections. human papillomavirus (HPV). Aged 18 to 24, they lodged a complaint for “involuntary bodily harm and aggravated deception”.
According to the lawyer, Me Camille Kouchner, these nine women “have in common to have contracted very debilitating diseases in the weeks and months following the vaccination when they had no medical history”. Five of them developed Verneuil’s disease, one developed lupus, another developed Guillain-Barré disease, one suffered from myasthenia gravis, and the last suffered from idiopathic hypersomnia.
The complaints do not specifically target the Sanofi Pasteur MSD laboratory, which in 2006 launched this vaccine against cervical cancer. “There are many players and we must seek the responsibility of each”, told AFP Me Camille Kouchner. These complaints are in addition to the one filed by Marie-Océane, the first young girl to file a complaint last November, who suffers from multiple sclerosis (MS) following her vaccination.
Since this complaint, the health authorities have reaffirmed that the benefit / risk balance of the vaccine was favorable. The National Medicines Safety Agency (ANSM) recalls that since its launch on the French market in November 2006, this vaccine has been the subject of reinforced national pharmacovigilance monitoring as part of a risk management plan ( National PGR) which complements a European PGR.
Currently, 435 cases of serious adverse effects including 135 of autoimmune diseases including 15 cases of MS have been reported to the national network of CRPVs (regional pharmacovigilance centers) and to the laboratory concerned for this vaccine. Figures to be compared to the 5 million doses of the Gardasil vaccine distributed in France since its marketing.
Furthermore, data from international and French literature do not show an increase in the incidence of autoimmune diseases or more particularly of MS after vaccination with Gardasil. “Health insurance data, relating to a cohort of nearly 2 million young girls born between 1992 and 1996 and followed over a period from 2008 to 2010, confirm these results”, specified the ANSM.
.
